Hims & Hers Health, Inc. (NYSE:HIMS) shares are trading higher Thursday after the company launched a compounded copy of the Wegovy pill at $49.
- Hims & Hers Health stock is surging to new heights today. Why are HIMS shares rallying?
Compounded Wegovy Offering Launched
Hims & Hers said it expanded its personalized weight loss portfolio by enabling providers to prescribe a compounded semaglutide pill, a needle-free option that uses the same active ingredient as Wegovy. The company said eligible customers can access treatment plans with an introductory offer starting at $49 for the first month.
Hims & Hers said the compounded semaglutide pill is formulated to protect the active ingredient during digestion and support absorption, allowing providers to tailor treatment for patients who prefer an oral option or are seeking to manage side effects. The company said pricing after the introductory period is $99 per month with a five-month plan, paid upfront.
CEO Andrew Dudum said the expansion is intended to increase choice on the platform and give providers more flexibility to individualize care. The company said its expanded facility footprint and integrated pharmacy and lab capabilities support lower pricing and broader access to personalized treatment plans.
Hims & Hers noted that compounded drug products are not approved by the FDA and are available as part of a holistic weight loss treatment plan if prescribed by a provider following an online consultation.
Hims & Hers Shares Surge Higher
HIMS Price Action: At the time of publication, Hims & Hers stock is trading 7.01% higher at $26.11, according to data from Benzinga Pro.
Image via Shutterstock
Recent Comments